# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Rudolph (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML036-SYN-TD
- Date: 1994-07-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gloria Haynes-Whitaker, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review three weeks after awake craniotomy, before radiotherapy with temozolomide. **S**

## History of present illness

Ms. Rudolph returns three weeks after an awake left frontal craniotomy. The surgeons removed all of the enhancing tumor, stopping at the mapped language sites, and the MRI the next day showed no residual enhancing tumor. Her speech was slower for three days after surgery and then came back to normal; she went home on the third day, having had heparin injections in hospital to prevent clots. She has had no seizure. The right hand is nearly back to normal, though fine buttons are still slow. The physical therapist saw her a week ago and gave her a home exercise program and a cane for uneven ground. She is now on dexamethasone 2 mg twice a day. Her fingerstick glucose readings at home have been 140 to 180 mg/dL after meals, and she is thirsty in the evenings. The pathology is glioblastoma, IDH-wildtype, with MGMT promoter methylation, and the tumor board has reviewed it with Dr. Brzezinski. She has met the radiation oncologist and had her planning scan, and starts radiotherapy with temozolomide on Monday. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Operation | Awake craniotomy with mapping; gross total resection of the enhancing tumor; home on day 3 |
| Pathology | Glioblastoma, IDH-wildtype, CNS WHO grade 4; TERT promoter mutation, EGFR amplification, +7/-10; MGMT promoter methylated |
| Function | Speech normal; right hand nearly normal; walking well |
| Steroid | Dexamethasone 2 mg twice a day; glucose up to 180 mg/dL after meals |
| Next | Radiotherapy 60 Gy in 30 fractions with daily temozolomide from Monday |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the afternoons; appetite larger on the steroid; weight up 1.6 kg |
| Neurological | Positive | Fine buttons slow with the right hand; no headache, seizure or speech difficulty |
| Endocrine | Positive | Thirsty in the evenings; glucose 140 to 180 mg/dL after meals |
| Musculoskeletal | Negative | No difficulty rising from a chair or climbing stairs |
| Integumentary | Negative | Incision healing; no redness or drainage |
| Cardiovascular | Negative | No leg swelling or calf pain |
| Psychiatric | Negative | Mood steadier; PHQ-9 6; no thoughts of self-harm |

7 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day **S**
- Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasone **S**
- Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stop **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/80 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 69.4 kg; BMI 21.4 kg/m². All vital signs are synthetic.

Hemoglobin: 12.6 g/dL; White cell count: 9.6 10*3/uL; Absolute neutrophil count: 7.2 10*3/uL; Absolute lymphocyte count: 1.1 10*3/uL; Platelets: 248 10*3/uL; Creatinine: 0.82 mg/dL; eGFR (CKD-EPI 1989): 85 mL/min/1.73 m²; ALT: 28 U/L; AST: 22 U/L; Total bilirubin: 0.5 mg/dL; Albumin: 4 g/dL; Glucose: 168 mg/dL (high); Karnofsky Performance Status: 90; PHQ-9: 6. All results are synthetic.

## Change since baseline

- Hemoglobin: 13.1 g/dL at baseline, 12.6 g/dL at this visit **S**
- White cell count: 7.1 10*3/uL at baseline, 9.6 10*3/uL at this visit **S**
- Platelets: 262 10*3/uL at baseline, 248 10*3/uL at this visit **S**
- Creatinine: 0.86 mg/dL at baseline, 0.82 mg/dL at this visit **S**
- eGFR (CKD-EPI 1989): 80 mL/min/1.73 m² at baseline, 85 mL/min/1.73 m² at this visit **S**
- Glucose: 92 mg/dL at baseline, 168 mg/dL (high) at this visit **S**
- Karnofsky Performance Status: 80 at baseline, 90 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 69.4 kg; blood pressure 132/80, pulse 76 |
| Head | Left frontal incision healed, staples out; no swelling or fluid collection |
| Mental status and speech | Fluent, no word-finding pauses; naming and repetition intact |
| Motor | No pronator drift; right grip 5-/5, finger tapping slightly slow; hip flexors 5/5 on both sides; rises from a chair without using her arms |
| Gait | Steady; tandem gait normal |
| Extremities | No leg swelling; calves soft; left calf slightly smaller than the right |
| Psychiatric | Focused and well informed; asks detailed questions |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Glioblastoma, IDH-wildtype, CNS WHO grade 4, left frontal, MGMT promoter methylated, after gross total resection** (C71.1). The integrated WHO CNS5 diagnosis is glioblastoma, IDH-wildtype: no IDH mutation on immunostaining or sequencing, with necrosis, microvascular proliferation, a TERT promoter mutation, EGFR amplification and chromosome 7 gain with 10 loss. MGMT promoter methylation and complete resection of the enhancing tumor in a fit woman of 54 are the most favorable factors this tumor has, and methylation predicts benefit from temozolomide. The tumor board recommends radiotherapy 60 Gy in 30 fractions with daily temozolomide 75 mg/m2 (140 mg for 1.84 m2), then six cycles of adjuvant temozolomide; tumor-treating fields will be discussed for the adjuvant phase. She was screened for open trials; none she was eligible for is open now. Baseline blood count, kidney and liver tests allow treatment. Hepatitis B, hepatitis C and HIV tests drawn today. **S**
   - Radiotherapy with temozolomide 140 mg at bedtime every day from Monday for six weeks.
   - Ondansetron 30 to 60 minutes before each dose.
   - Sulfamethoxazole-trimethoprim three times a week from the first day of temozolomide.
   - Blood count weekly at the radiation clinic.
   - Do not drive.
2. **Vasogenic cerebral edema, better after resection** (G93.6). Edema and midline shift less on the postoperative MRI; no headache. The taper can continue. **S**
   - Dexamethasone 2 mg daily for one week, then 1 mg daily for one week, then stop.
   - Report headache, nausea or new weakness during the taper.
3. **Steroid-induced hyperglycemia** (R73.9). Random glucose 168 mg/dL with home readings up to 180 after meals on dexamethasone, from an A1c of 5.6% before steroids: steroid-induced hyperglycemia, expected to resolve with the taper. No drug treatment is needed at these levels. **S**
   - Fingerstick glucose before supper daily until off dexamethasone.
   - Call for readings above 250 mg/dL.
   - Fewer sweet drinks and refined carbohydrates while on the steroid.
4. **Late effects of childhood poliomyelitis** (B91). Legs strong on both sides and gait steady. The physical therapist found mild right-sided weakness after surgery on top of a left calf that was weakened by polio in childhood; her risk of falling is higher during treatment because of fatigue, steroid effects on muscle, and any change in the tumor. **S**
   - Home exercise program and a cane for uneven ground.
   - Leg strength at each visit.
5. **Left frontal mass, presumed high-grade glioma** (D49.6). Superseded by the pathology. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Integrated WHO CNS5 diagnosis | On the surgical specimen | Up to date | Glioblastoma, IDH-wildtype, CNS WHO grade 4: IDH1 R132H negative and no IDH1 or IDH2 mutation on sequencing; ATRX retained; TERT promoter mutation; EGFR amplification; +7/-10; CDKN2A deleted; H3 and BRAF wild-type |
| Laboratory | MGMT promoter methylation | On the surgical specimen | Up to date | Methylated |
| Imaging | MRI within 48 hours of surgery | After resection, as the baseline for radiotherapy planning | Up to date | The day after surgery: no residual enhancing tumor |
| Laboratory | Blood count with neutrophils, lymphocytes and platelets | Baseline before temozolomide | Completed today | Hemoglobin 12.6 g/dL, white cells 9.6, neutrophils 7.2, lymphocytes 1.1, platelets 248 |
| Laboratory | Kidney and liver tests | Baseline before temozolomide | Completed today | Creatinine 0.82 mg/dL, eGFR 85; ALT 28, AST 22 U/L, bilirubin 0.5 mg/dL, albumin 4.0 g/dL |
| Laboratory | Glucose on dexamethasone | At each visit while on a steroid | Completed today | 168 mg/dL random; home readings 140 to 180 after meals |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before chemotherapy | Ordered | Drawn today |
| Medication safety | Dexamethasone taper | As soon as symptoms allow after surgery | Completed today | 2 mg twice a day now; 2 mg daily for a week, 1 mg daily for a week, then stop |
| Medication safety | Pneumocystis pneumonia prophylaxis | Throughout concurrent temozolomide | Ordered | Sulfamethoxazole-trimethoprim three times a week from the first day |
| Medication safety | Antiemetic before temozolomide | Each dose | Ordered | Ondansetron 30 to 60 minutes before the bedtime dose, on an empty stomach |
| Medication safety | Seizure history and antiseizure drug need | Each visit | Not indicated | No seizure before or after surgery; no antiseizure drug |
| Examination | Neurologic examination (language, strength, gait) | Each visit | Completed today | Speech normal; right grip 5-/5 with slightly slow finger tapping; gait steady |
| Examination | Signs of leg clot or pulmonary embolism | Each visit | Completed today | No leg swelling or calf tenderness; hospital prophylaxis given after surgery; no routine prophylaxis at home |
| Survey | Performance status (Karnofsky) | Each visit | Completed today | Karnofsky 90 |
| Referral | Physical therapy | After surgery when weakness or fall risk is present | Up to date | Assessed a week ago: home program and a cane for uneven ground |
| Referral | Radiation oncology and clinical trial screening | After the integrated diagnosis | Up to date | Planning scan done; no eligible trial open |
| Self-management | Falls, leg strength and late effects of polio | Each visit | Completed today | No falls; legs 5/5; no new weakness, fatigue or pain in the polio-affected leg |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 6; no thoughts of self-harm |

## Goal progress

- MRI of the brain within 24 hours and a neuro-oncology and neurosurgery plan within one week of presentation. Outcome by 1994-07-02: MRI the next morning; consultation three days after the first visit. **S**
- Maximal safe resection within two weeks of the MRI, preserving language and right-hand strength. Outcome by 1994-07-29: Gross total resection of the enhancing tumor nine days after the first visit; speech back to normal within days and right-hand strength nearly normal. **S**
- Radiotherapy with daily temozolomide started within six weeks of surgery and completed on schedule. In progress; target 1994-09-14. **S**
- Dexamethasone tapered off within five weeks of surgery, with glucose back to normal. In progress; target 1994-09-14. **S**
- No falls, and walking independently, through treatment. In progress; target 1994-10-09. **S**
- Palliative care involved and her wishes recorded before adjuvant treatment begins. In progress; target 1994-10-09. **S**

## Medication changes

- Stopped: Dexamethasone 2 mg oral tablet, one tablet twice a day after surgery, tapering **S**
- Started: Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stop **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026), National Comprehensive Cancer Network
- Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18(3):170-186 (PMID 33293629) (2021), European Association of Neuro-Oncology
- Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231-1251 (PMID 34185076) (2021), Neuro-Oncology (WHO Classification of Tumours)
- Mohile NA, et al. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. J Clin Oncol 2022;40(4):403-426 (PMID 34898238) (2022), American Society of Clinical Oncology and Society for Neuro-Oncology
- Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996 (PMID 15758009) (2005), New England Journal of Medicine
- Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003 (PMID 15758010) (2005), New England Journal of Medicine
- Wen PY, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 2023 (PMID 37774317) (2023), Response Assessment in Neuro-Oncology working group (Journal of Clinical Oncology)
- TEMODAR (temozolomide) capsules, prescribing information (2026), U.S. National Library of Medicine, DailyMed (Merck Sharp & Dohme label)
- Walbert T, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 2021;23(11):1835-1844 (PMID 34174071) (2021), Society for Neuro-Oncology and European Association of Neuro-Oncology
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023), American Society of Clinical Oncology
- Farbu E, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Eur J Neurol 2006;13(8):795-801 (PMID 16879288) (2006), European Federation of Neurological Societies
- CMID: Clinical Monitoring Intelligence Database, depression monograph (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Radiotherapy with temozolomide from Monday for six weeks, with weekly blood counts at the radiation clinic. Primary care review at the end of radiotherapy. Call for fever, bruising, a seizure, new weakness or headache. **S**
- Next scheduled visit 1994-09-14: end of six weeks of radiotherapy with daily temozolomide: blood counts, liver tests, Pneumocystis prophylaxis, fatigue, mood, tumor-treating fields and an early palliative care referral. **S**
